TCR deal spree intensifies as Roche commits up to $2B in Adaptive Biotech to develop personalized cancer drugs
The appetite for TCR therapies and their potential to target solid tumors — a limitation of existing cellular therapies — has burgeoned, fueling a string of deals. On Friday, Roche’s Genentech agreed to fork out a meaty $300 million upfront for access to Adaptive Biotechnologies’ tech platform, which is designed to identify T-cell receptors (TCRs) for therapeutic use. The deal, which offers Adaptive up to $2 billion over time in milestone payments, will be used to develop personalized cancer therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.